Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematological and Solid Tumor Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD43/SPN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD43/SPN ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD43 Products |
| Gene Delivery | CD43/SPN Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to preserve native conformation and complex glycosylation. |
View CD43 Products |
| Benchmark Ab | Anti-CD43/SPN Recombinant Antibody Recombinant positive control derived from benchmark clinical/preclinical sequences. |
View CD43 Products |
| Validator | CD43/SPN siRNA Set For target knockdown verification and specificity validation. |
View CD43 Products |
| Related Target A | CD33 Myeloid lineage marker; frequently co-evaluated with CD43 in acute myeloid leukemia (AML) profiling. |
View CD33 Products |
| Related Target B | CD47 "Don't eat me" signal; co-expressed on myeloid malignancies, evaluated for synergistic combination therapies. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-dependent epitope binding | HEK293 mammalian expression system ensures native post-translational modifications (PTMs) and proper sialylation. |
| Conformation-sensitive cell-based screening | Lentiviral transduction vectors enable stable cell line construction for flow cytometry and ADCC assays without VLP-associated instability. |
| Lack of positive control benchmarks | Sequence-verified clinical benchmark antibodies (biosimilars) available for comparative binding studies. |
| Off-target cross-reactivity risks | High-purity recombinant proteins (>95% by SDS-PAGE) ensure clean baseline screening and minimal assay background. |
Live CD43/SPN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD43/SPN therapeutics is intensifying, with major players shifting focus from traditional mAbs to tumor-associated glycoform-specific antibodies and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific glyco-epitopes of CD43 to avoid on-target, off-tumor toxicity on healthy hematological cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Glyco-specific) | Academic Institutions, Biotech Startups | Leukemia, Lymphoma, Solid Tumors | Epitope specificity validation (Requires HEK293-expressed CD43 with native sialylation) |
| CAR-T / Cell Therapy | Clinical-stage Biotechs | Acute Myeloid Leukemia (AML) | Stable cell line construction (Requires Lentiviral vectors for robust target expression) |
| Antibody-Drug Conjugates (ADCs) | Oncology-focused Biopharma | Solid Tumors (Breast, Colon) | Internalization assays (Requires high-purity ECD-Fc fusion proteins for conjugation validation) |